[O8] Oral Session 8　Lung Cancer / Thoracic Cancer 2（Immune Checkpoint Inhibitors）
【E】

[O8-2] Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

^○Haruhiro Saito¹, Melissa L Johnson², Byoung Chul Cho³, Alexander Luft⁴, Jorge A. Alatorre-Alexander⁵, Sarayut Lucien Geater⁶, Konstantin Laktionov⁷, Aleksandr Vasiliev⁸, Dmytro Trukhin⁹, Sang-We Kim¹⁰, Grygorii Ursol¹¹, Maen Hussein¹², Farah Louise Lim¹³, Cheng-Ta Yang¹⁴, Luiz Henrique Araujo¹⁵, Niels Reinmuth¹⁶, Xiaojin Shi¹⁷, Lynne Poole¹⁸, Solange Peters¹⁹, Edward B. Garon²⁰, Tony Mok²¹ (1.Kanagawa Cancer Center, Yokohama, Japan, 2.Sarah Cannon Research Institute, Tennessee Oncology, PLLCC, Nashville, TN, USA, 3.Yonsei Cancer Center, Seoul, Korea, 4.Leningrad Regional Clinical Hospital, St Petersburg, Russia, 5.Health Pharma Professional Research, Mexico City, Mexico, 6.Prince of Songkla University, Songkhla, Thailand, 7.Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia, 8.“Private Health Institution “Clinical Hospital” RZD-Medicine”, St Petersburg, Russia, 9.Odessa Regional Oncological Dispensary, Odessa, Ukraine, 10.Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 11.Acinus, Kropyvnytskyi, Ukraine, 12.Florida Cancer Specialists – Sarah Cannon Research Institute, Leesburg, FL, USA, 13.Queen Mary University of London, London, United Kingdom, 14.Chang Gung Memorial Hospital, Taoyuan City, Taiwan, 15.Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil, 16.Asklepios Lung Clinic, Munich-Gauting, Germany, 17.AstraZeneca, Gaithersburg, MD, USA, 18.AstraZeneca, Cambridge, UK, 19.Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland, 20.David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 21.Chinese University of Hong Kong, Hong Kong, China)